Agendia’s MammaPrint Receives Positive Coverage Decisions from Three Major Private Healthcare Insurers

May 1, 2018

Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of Clinical Oncology (ASCO) guidelines recommending MammaPrint® Breast Cancer Risk of Recurrence Test for certain breast cancer patients Majority of U.S. breast cancer patients will now be covered for MammaPrint, which could result in significant cost savings IRVINE, CA AND AMSTERDAM,…

Read more

Agendia Announces CE Mark for NGS-Based MammaPrint BluePrint Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe

March 21, 2018

IRVINE, CA, AMSTERDAM, NETHERLANDS – 21 March 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe. Dr. Marjolaine Baldo, Commercial Vice…

Read more

Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint BluePrint Breast Cancer Kit to Market

December 19, 2017

IRVINE, CA, AMSTERDAM, and RIJSWIJK, NETHERLANDS – 19 December 2017 – Agendia, Inc, a world leader in personalized medicine and molecular cancer diagnostics, and Bluebee, a company driving global genomic data-driven medicine, have partnered to provide a secure, convenient, data processing solution for Agendia’s MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit, which is…

Read more

Key Studies Presented at the San Antonio Breast Cancer Symposium Demonstrate the Important Role of MammaPrint for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients

December 12, 2017

  Data from the I-SPY 2 trial showed the first long-term survival results for patients pre-selected as MammaPrint high-risk, with 94% of the patients who achieved pathological complete response event-free at three years MammaPrint assessment is cost effective in clinical high risk patients compared to clinical risk assessment alone Additional data from MINDACT trial confirmed…

Read more